Financhill
Back

Hisamitsu Pharmaceutical Quote, Financials, Valuation and Earnings

The dark truth about AI

Click here to learn more...
Buy
52

HTSUF
Hisamitsu Pharmaceutical

Last Price:
24.56
Seasonality Move:
3.79%

7 Day Trial

ALL ACCESS PASS

$ 7

Zero Day Options Trade LIVE Tuesday at 2 p.m. ET!

Discover The Zero Day Loophole (BEFORE Tues at 2 p.m. ET!)

Hisamitsu Pharmaceutical Price Quote

$24.56

Hisamitsu Pharmaceutical Key Stats

Buy
52
Hisamitsu Pharmaceutical (HTSUF) is a Buy

Day range:
$24.56 - $24.56
52-week range:
$23.70 - $34.00
Dividend yield:
2.36%
P/E ratio:
19.35
P/S ratio:
1.85
P/B ratio:
0.96%

Volume:
0
Avg. volume:
0
1-year change:
-27.77%
Market cap:
$1.8B
Revenue:
$991.5M
EPS:
$1.29

How Much Does Hisamitsu Pharmaceutical Make?

Is Hisamitsu Pharmaceutical Growing As A Company?

Hisamitsu Pharmaceutical Stock Price Performance

What Is Hisamitsu Pharmaceutical 52-Week High & Low?

Hisamitsu Pharmaceutical Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Hisamitsu Pharmaceutical?

Is Hisamitsu Pharmaceutical Cash Flow Positive?

Data Unavailable

Hisamitsu Pharmaceutical Return On Invested Capital

  • Is Management Doing A Good Job?
    HTSUF return on invested capital is 5.3%
  • What Is Hisamitsu Pharmaceutical Return On Assets?
    ROA measures how assets are converting to revenues and is 4.26%
  • What Is HTSUF Return On Equity?
    ROE is a measure of profitability and is 5.33%

Hisamitsu Pharmaceutical Earnings Date & Stock Price

Hisamitsu Pharmaceutical Competitors

Hisamitsu Pharmaceutical Dividend Yield

Hisamitsu Pharmaceutical Analyst Estimates

YoY Growth Past Surprise
EPS: -3.11% 0%
Revenue: 5.35% 0%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 0.00
Downside from Last Price: -100%

Major Shareholders

  • How many HTSUF shares are owned by institutional investors?
    10.3M HTSUF shares are owned by institutional investors
  • How many HTSUF shares are owned by insiders?
    0 HTSUF shares are owned by insiders